NovaBay Appoints CEO Justin Hall to its Board of Directors
August 24 2020 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the appointment of President and CEO Justin Hall to the Company’s
board of directors, effective August 21, 2020. Mr. Hall has been
with NovaBay for seven years in various capacities, and fills a
vacancy on the board following the resignation of Xiaopei (Ray)
Wang. Board membership remains at six, including three independent
directors.
Mr. Hall will serve as a Class II director, and will stand for
reelection to a three-year term at the 2021 NovaBay annual meeting
of stockholders.
“Serving as chief executive for the past 18 months, Justin has
proven to be a highly capable leader who is well respected by the
NovaBay staff and business partners,” said NovaBay Chairman of the
Board Paul E. Freiman. “He successfully spearheaded a major shift
in U.S. commercial strategy to broaden sales of our flagship
product, Avenova®, from prescription only to include the direct to
consumer channel. Online unit sales have subsequently become an
increasing portion of our core business, with consumers continuing
to have access to our product during the COVID-19 pandemic without
interruption and without leaving their homes.
“He tapped our international health network early in the U.S.
pandemic for personal protective equipment when supply of these
important items was severely limited. More recently, he led efforts
to secure funding and improve our capital structure, providing our
Company with financial security during these uncertain times. The
board acknowledges his leadership and welcomes his membership. On
behalf of the board, I would also like to extend sincere thanks to
Ray for his service over the past two years,” added Mr.
Freiman.
“It’s exciting to take this next step at NovaBay as we navigate
the pandemic while moving toward future growth,” said Mr. Hall. “I
see significant opportunities ahead to build on our current
business with new products and expanded markets. I have developed a
close working relationship with the board over my years with the
Company, and appreciate their confidence.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market and NEUTROPHASE® for the wound care market. The
Aganocide compounds, still under development, have target
applications in dermatology and urology.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the relationship
between the Board and management, and how that may affect future
financial performance of NovaBay Pharmaceuticals, Inc. This release
contains forward-looking statements that are based upon
management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our pandemic related marketing
strategies as well as any effect that these marketing activities
may have on the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the possibility that the available market
for the Company’s products will not be as large as expected, the
Company’s products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to meet the
Company’s cash needs, and any potential regulatory problems. Other
risks relating to NovaBay’s business, including risks that could
cause results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on
NovaBay’s progress
Like us on Facebook Follow us on Twitter Connect
with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200824005056/en/
NovaBay Justin Hall Chief
Executive Officer and General Counsel 510-899-8800
jhall@novabay.com Investors LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024